For patients with localized prostate cancer, treatment selection increasingly involves more than choosing between radical prostatectomy and radiation therapy. Advances in multiparametric imaging, molecular imaging, and focal ablative technologies are creating another consideration for a carefully selected subset of patients: treating the clinically significant lesion while limiting exposure of uninvolved prostate tissue and adjacent functional structures.

That approach was used in the treatment of 76-year-old Pedro Lopez, who was diagnosed with localized, intermediate-risk prostate cancer after an abnormal screening evaluation led to imaging and biopsy. According to his physicians, concordant findings on MRI, targeted biopsy and prostate-specific membrane antigen positron emission tomography (PSMA PET) localized his disease to a discrete area of the prostate.

That concordance made Mr. Lopez a candidate for focal therapy using high-intensity focused ultrasound, or HIFU.

“For patients with intermediate-risk localized prostate cancer, there are multiple treatment options in terms of curative-intent treatment,” explains Manuel Ozambela, Jr., M.D., urologic surgical oncologist at Baptist Health Herbert Wertheim Cancer Institute. “Those include radical surgery to remove the prostate [and] radiation therapy to radiate the entire gland. And now we also have options for focal treatments.”

From whole-gland treatment to lesion-directed therapy

Traditional curative-intent treatment for localized prostate cancer commonly involves treatment of the entire prostate. Radical prostatectomy removes the gland, while definitive radiation therapy exposes the gland to therapeutic radiation. Both remain established approaches with important roles across the prostate cancer risk spectrum.

Focal therapy is conceptually different. Rather than treating the entire prostate, the strategy is to identify and ablate the area containing clinically significant disease while preserving as much surrounding tissue as possible.

“With focal therapy, the goal is, instead of treating the entire gland, if we can identify the area of the gland that has the disease and focus treatment solely on that area, we are able to avoid some of that collateral damage and in turn improve the patient’s quality of life,” Dr. Ozambela said.

Patient selection is therefore fundamental.

Mr. Lopez had what Dr. Ozambela described as a focal lesion visible on MRI. MRI-ultrasound fusion biopsy confirmed prostate cancer within the target. PSMA PET subsequently provided molecular imaging information about both the location and apparent distribution of disease. According to Dr. Ozambela, the MRI, biopsy and PSMA PET findings were concordant, with evidence of disease confined to one region of the prostate.

That is substantially different from a patient with multifocal disease.

“Not every patient is a candidate for focal therapy,” Dr. Ozambela emphasized. “A lot of patients may have multifocal disease, meaning tumors in multiple parts of the prostate. That wouldn’t be a good candidate for this type of treatment.”

HIFU as the Ablative Platform

HIFU uses focused ultrasound energy to generate thermal ablation within a defined tissue volume. The treatment does not require a surgical incision. In prostate applications, ultrasound energy is delivered transrectally and concentrated within the planned treatment zone.

“HIFU means high-intensity focused ultrasound,” explained Murugesan Manoharan, M.D., surgical urologic oncologist and the chief of urologic oncology surgery at Baptist Health Herbert Wertheim Cancer Institute and Abbhi Family Endowed Chair in Urologic Oncology. “It allows me to destroy or ablate the cancer tissue without affecting the nearby normal tissues.”

The anatomical proximity of the prostate to the external urinary sphincter, neurovascular structures and rectum makes treatment precision clinically consequential. Damage to structures involved in continence and erectile function can have substantial quality-of-life implications after prostate cancer therapy.

“When you’re treating patients with prostate cancer, apart from curing the cancer, quality of life is important,” Dr. Manoharan said. He specifically identified urinary continence and preservation of the nerves involved in sexual function as important considerations during treatment planning.

HIFU itself is not new. What was different in Mr. Lopez’s case, according to his physicians, was the integration of PSMA PET information into HIFU treatment planning, supplemented by AI-based tools.

“HIFU has been around for a long time,” Dr. Ozambela said. “What’s novel here is that we’re able to integrate molecular imaging, being the PSMA PET scan, and in the treatment-planning phase, we can also integrate some AI protocols to better help design treatment and plan treatment.”

Dr. Ozambela described Mr. Lopez during the interview as the first patient to undergo PSMA fusion-guided HIFU using this integrated approach. Because that “first” designation comes from the treating physician’s interview rather than an independently supplied publication or registry, it is best presented as an attributed institutional clinical milestone rather than an independently established universal first.

PSMA PET Adds Molecular Information to Anatomic Targeting

For focal therapy to be effective, clinicians need confidence that the intended target accurately represents the clinically relevant disease.

MRI provides detailed anatomic visualization of the prostate. Targeted fusion biopsy provides histopathologic confirmation. PSMA PET adds a different layer of information by visualizing prostate cancer-associated molecular activity.

“The PSMA PET scan is a special scan which identifies the cancer within the prostate and also tells me whether there’s a cancer outside the prostate or not,” Dr. Manoharan said.

In Mr. Lopez’s case, the treating team used agreement among MRI, fusion biopsy and PSMA PET to support focal treatment selection and delineation.

Dr. Ozambela described the sequence this way: MRI identified the lesion, fusion biopsy established the diagnosis and molecular imaging helped characterize the lesion’s location and activity. The three modalities pointed to disease in the same focal region.

The clinical value, therefore, was not simply the availability of another image. It was the ability to synthesize complementary sources of information before ablating only a portion of the gland.

Defining the Role of Artificial Intelligence

The interviews also make an important distinction about AI that can be obscured when the technologies are grouped together.

AI, PSMA PET and HIFU are not a single treatment modality.

“The term AI — these are basically three different things,” Dr. Ozambela said. “AI is one thing, PSMA PET is one thing and then HIFU is another thing.”

In this case, HIFU was the therapeutic modality. PSMA PET contributed molecular imaging data. AI-based platforms were incorporated into image review and treatment planning to help clinicians interpret information and define the treatment target.

Dr. Manoharan characterized the goal of that integration as increasing precision while protecting uninvolved structures.

“The artificial intelligence … puts them together and allows the surgeon to know exactly where the treatment should be provided,” he said. “That way, I’m able to … maintain the vital structures such as the sexual nerves as well as sphincter, so that the patient’s quality of life is well maintained.”

The physicians also view AI’s potential role as broader than procedure planning.

Dr. Ozambela identified three areas in which he expects AI to influence focal prostate cancer therapy: patient selection, treatment planning and intraoperative decision-making, and post-treatment risk stratification and surveillance.

The last component is particularly important in focal therapy. Because untreated prostate tissue remains, patients require ongoing surveillance for persistent, recurrent or de novo disease outside the ablation zone.

“These patients, because we do focal therapy, we haven’t treated their entire gland,” Dr. Ozambela said. “We have to follow them closely to make sure they never have a recurrence outside of our treatment zone.”

He anticipates that integrating longitudinal post-treatment data with AI may eventually help clinicians identify which patients require intensified surveillance.

Functional Outcomes Remain Part of the Treatment Equation

Mr. Lopez’s short-term clinical course illustrates one of the principal reasons focal therapy is of interest.

According to his interview, he required a urinary catheter for approximately one week and described returning to near-baseline activity within roughly a week and a half.

At follow-up, Dr. Ozambela reported excellent urinary control, no urinary complaints and good sexual function.

“He’s essentially the same as he was before treatment,” Dr. Ozambela said.

A single patient outcome cannot establish comparative efficacy or toxicity, but the case demonstrates the clinical objective underlying focal therapy: maintain oncologic control while reducing treatment-related morbidity in patients whose disease characteristics make lesion-directed treatment appropriate.

Selection Rather Than Technology Should Drive Treatment

Both physicians repeatedly returned to an important principle: availability of a new technology does not make it appropriate for every patient.

Cancer distribution, tumor characteristics, imaging and biopsy findings, patient priorities and tolerance for longitudinal surveillance all inform treatment selection. Patients with multifocal or otherwise unsuitable disease may be better served by radical prostatectomy, radiation therapy or another treatment strategy.

“We don’t have to make the patient fit the treatment,” Dr. Ozambela said. “We pick the right treatment for the right patient.”

That distinction becomes increasingly important as the prostate cancer treatment portfolio expands. Innovation has the greatest clinical value when it increases the ability to individualize care rather than simply adding another procedure.

For Dr. Manoharan, that philosophy can be summarized by three goals: cancer treatment, preservation of quality of life and timely return to normal activity.

For appropriately selected patients with localized disease, the integration of MRI, targeted biopsy, PSMA PET and focal HIFU may provide another pathway toward those goals. At the same time, Dr. Ozambela’s comments underscore that focal therapy introduces its own clinical obligation: careful patient selection and continued surveillance of the untreated gland.

As imaging, computational tools and focal-treatment platforms continue to evolve, the more significant shift may be not toward one preferred technology, but toward increasingly precise matching of treatment intensity to individual disease biology, anatomy and patient priorities.